"Epirubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
| Descriptor ID |
D015251
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175.200 D04.615.562.050.200.175.200 D09.408.051.059.200.175.200
|
| Concept/Terms |
Epirubicin- Epirubicin
- 4'-Epidoxorubicin
- 4' Epidoxorubicin
- 4'-Epi-Doxorubicin
- 4' Epi Doxorubicin
- 4'-Epi-Adriamycin
- 4' Epi Adriamycin
- 4'-Epiadriamycin
- 4' Epiadriamycin
- 4'-Epi-DXR
- 4' Epi DXR
Ellence- Ellence
- Pharmorubicin
- Farmorubicine
- Farmorubicin
|
Below are MeSH descriptors whose meaning is more general than "Epirubicin".
Below are MeSH descriptors whose meaning is more specific than "Epirubicin".
This graph shows the total number of publications written about "Epirubicin" by people in this website by year, and whether "Epirubicin" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 3 | 3 | 6 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 2 | 3 |
| 2012 | 0 | 4 | 4 |
| 2013 | 1 | 1 | 2 |
| 2015 | 0 | 2 | 2 |
| 2016 | 1 | 3 | 4 |
| 2017 | 0 | 3 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2025 | 0 | 1 | 1 |
Below are the most recent publications written about "Epirubicin" by people in Profiles.
-
Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial. Nat Med. 2025 Feb; 31(2):442-448.
-
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer. Breast Cancer Res Treat. 2022 Feb; 192(1):153-161.
-
Predictors and significance of histologic response to neoadjuvant therapy for gastric cancer. J Surg Oncol. 2021 May; 123(8):1716-1723.
-
Chemoablation in Urothelial Carcinoma: A Systematic Review and Future Perspectives. Urology. 2020 10; 144:28-37.
-
A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma. Clin Cancer Res. 2020 08 15; 26(16):4225-4232.
-
Three cases of advanced cutaneous squamous cell carcinoma treated with a combination of carboplatin and epirubicin. Eur J Hosp Pharm. 2020 03; 27(2):128.
-
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol. 2017 Nov 10; 35(32):3671-3677.
-
Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy. Cancer. 2018 Jan 01; 124(1):36-45.
-
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017 06; 18(6):812-822.
-
A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial. Oncotarget. 2016 Aug 02; 7(31):49099-49106.